Products

CAT # Product Name Description
CPD107464 Nirogacestat Nirogacestat, also known as PF-03084014, is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors. Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Nirogacestat enhances docetaxel-mediated tumor response and provides a rationale to explore GSIs as adjunct therapy in conjunction with docetaxel for men with CRPC (castration-resistant prostate cancer).
CPD112464 (S)-3-(3-amino-4-chlorophenyl)-3-cyclopropylpro...
CPD112465 (2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-me...
CPD110957 SJ-03
CPD108743 AZD-5305 AZD5305 is a potent, selective and oral active PARP inhibitor. AZD5305 is a highly potent inhibitor of PARP1, with significant PARP1-DNA trapping activity, no PARP2-activity, nor binding activity to any other members of the PARP family. AZD5305 has excellent secondary pharmacology and physicochemical properties as well as high oral bioavailability in preclinical species.
CPD107417 UT-34 UT-34 is a selective androgen receptor degrader (SARD) ligand.
CPD109065 ART558 Art558 is a nanomolar, efficient, selective, low molecular weight, allosteric DNA polymerase pol θ Inhibitor (ic50=7.9 nm). Art558 can be used in cancer research.
CPD109527 2-chloro-4-[trans-3-amino-2,2,4,4-tetramethylcy... Ar agonist 1 (compound 29) is an effective ar antagonist, which binds to E3 ligase ligand and has weak binding affinity with VHL protein. It is used to synthesize protac ard-266 (hy-133020).
CPD111380 APOL1-IN-1 Kif18a-in-1 is an inhibitor of APOL1 APOL1, which can be used in the study of focal segmental glomerulosclerosis (FSGS) and non diabetes nephropathy (ndkd). For details, please refer to compound 87 in patent document wo2020131807a1.
CPD107416 UT-155 UT-155 is a potent selective androgen receptor degrader (SARD), markedly reducing the activity of wild-type and splice variant isoforms of AR, binding the amino-terminal transcriptional activation domain AF-1 and the carboxy-terminal ligand binding domain.
CPD109440 NBI-921352 NBI-921352 is a potent, highly selective Nav1.6 sodium channel inhibitor being developed to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other potential indications, including adult focal epilepsy.
CPD109136 TPX-0046, Enbezotinib Enbezotinib is a tyrosine kinase inhibitor, RET autophosphorylation inhibitor, and antineoplastic agent.
CPD109334 (2s,4s)-2-(3-((3-chloro-4-methylbenzyl)oxy)azet...
CPD106632 M2N12 M2n12 is an effective and highly selective inhibitor of cyclin phosphatase 25C (cdc25c), with an IC50 value of 0.09 μ M。 M2n12 also has the activity of inhibiting CDC25A and CDC25B, with IC50 values of 0.53 respectively μ M and 1.39 μ M。 M2n12 has antitumor activity and can be used in cancer research.
CPD101731 GDC-9545
CPD108485 ARV-110,Bavdegalutamide Bavdegalutamide, also known as ARV-110, is a first-in-class PROTAC that effectively targets the wild type Androgen Receptor (AR) and certain genomic alterations of the AR (amplification, T878A, H875Y, F877L, M895V, but not L702H or AR-V7) for degradation in both enzalutamide sensitive and resistant preclinical models. ARV-110 showed promising anti-tumor activity in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC).
CPD101749 4-[(S)-4-Boc-2-methyl-1-piperazinyl]-6-fluoro-7...
CPD108323 Runcaciguat Runcaciguat, also known as BAY 1101042, is a novel, potent, and orally active sGC activator. Runcaciguat activated the sGC reporter cell line with an EC50 value of 11.2 ± 1.0 nM. Pretreatment of the sGC reporter cell line with 30 μM ODQ for 3 h resulted in an increased potency of runcaciguat (EC50 of 2.1 ± 0.07 nM), and treatment of the reporter cells with runcaciguat in combination with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) (10 and 100 nM) showed additive effects. Treatment with runcaciguat resulted in maximal luminescence signals in the range of 50–60% in comparison to the sGC activator cinaciguat. Given the broad impact of oxidative stress in cardiovascular and cardiorenal diseases, runcaciguat might become a new treatment modality for a broad variety of diseases in these indication space but also beyond.
CPD108593 PF-07321332 Nirmatrelvir, also known as PF-07321332 (brand name: Paxlovid), is an orally bioavailable 3C-like protease (3CLPRO) inhibitor and SARS-CoV-2 Mpro inhibitor. This drug is being investigated for safety, tolerability, and pharmacokinetics before moving on to studies of efficacy in the treatment or prophylaxis of COVID-19. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. PF-07321332 is an oral COVID-19 antiviral clinical candidate. By inhibiting the main protease, PF-07321332 prevents the virus from cleaving long protein chains into the parts it needs to reproduce itself.
CPD111460 2-Chloro-8-[(1S)-1-cyclopropylethyl]-6-[[[6-(me...
CPD110961 SJ-07
CPD111459 N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-...
CPD110960 SJ-06
CPD111108 1,3,5-Triazine-2,4(1H,3H)-dione, 3-(1,1-dimethy...


Contact Us

Inquiry

Latest News

  • Top 7 Trends In Pharmaceutical Research In 2018

    Top 7 Trends In Pharmaceutical Research I...

      Being under ever-increasing pressure to compete in a challenging economic and technological environment, pharmaceutical and biotech companies must continually innovate in their R&D programmes to stay ahead ...

  • ARS-1620: A promising new inhibitor for KRAS-mutant cancers

    ARS-1620: A promising new inhibitor for K...

    According to a study published in Cell, researchers have developed a specific inhibitor for KRASG12C called ARS-1602 that induced tumor regression in mice. “This study provides in vivo evidence that mutant KRAS can be...

  • AstraZeneca receives regulatory boost for oncology drugs

    AstraZeneca receives regulatory boost for...

    AstraZeneca received a double boost for its oncology portfolio on Tuesday, after US and European regulators accepted regulatory submissions for its drugs, the first step towards winning approval for these medicines. ...

WhatsApp Online Chat !